Clinical practice of an endocrinology clinical pharmacists participating in the treatment of a patient with diabetes and hyperprolactinemia

WANG Tao; DENG Ang

doi:10.3969/j.issn.1006-0111.2015.02.020

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To explore the working pattern for endocrinology clinical pharmacists participating in clinical drug treatment. Methods By participating in the treatment for a patient with diabetes and hyperprolactinemia and analyzing the causes of poor glycemic control and hyperprolactinemia, clinical pharmacists proposed therapeutic regimen. Results The long-term psychotropic medication may be one of the reasons why blood glucose of the patient was unsatisfactorily controlled. The patient with hyperprolactinemia may be associated with her longstanding use of paliperidone. The patient was recommended to consult a psychiatrist and switch to an alternative medication which does not cause hyperprolactinemia. Conclusion The active participation of clinical pharmacists during clinical drug therapy could improve the medication rationality and compliance of patients with drugs.

Clinical practice of an endocrinology clinical pharmacists participating in the treatment of a patient with diabetes and hyperprolactinemia

1. Department of Pharmacy, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221006, China

2. Department of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China

Received Date: 2014-02-17

Rev Recd Date: 2014-09-22

Key words:

Abstract: Objective To explore the working pattern for endocrinology clinical pharmacists participating in clinical drug treatment. Methods By participating in the treatment for a patient with diabetes and hyperprolactinemia and analyzing the causes of poor glycemic control and hyperprolactinemia, clinical pharmacists proposed therapeutic regimen. Results The long-term psychotropic medication may be one of the reasons why blood glucose of the patient was unsatisfactorily controlled. The patient with hyperprolactinemia may be associated with her longstanding use of paliperidone. The patient was recommended to consult a psychiatrist and switch to an alternative medication which does not cause hyperprolactinemia. Conclusion The active participation of clinical pharmacists during clinical drug therapy could improve the medication rationality and compliance of patients with drugs.

HTML

Reference (21)

[1]	黎燕, 罗维肖. 非典型抗精神病药与糖尿病关系的研究[J]. 临床精神医学杂志, 2002, 12(5):299-300.
[2]	林琳, 瞿发林. 抗精神病药所致高催乳素血症的防治进展[J]. 实用药物与临床, 2010, 13(4):290-292.
[3]	牟晓东, 张志. 抗精神病药物治疗与血糖调节紊乱[J]. 国外医学精神病学分册, 2004, 31(2):86-88.
[4]	娄素琴, 杨广声, 钱东丽. 抗精神病药物引起血糖升高135例[J]. 医药导报, 2006, 25(10):1009.
[5]	Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes[J]. Diabetes Obes Metab, 2006, 8(2):125-135.
[6]	Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature[J]. J Clin Psychiatr, 2001, 62 (Suppl 7): 22-31.
[7]	Lu CH, Yan YH. Risperidone-associated newly diagnosed diabetes and fatal diabetes ketoacidosis in a young schizophrenic patient[J]. Diabetes Res Clin Pract, 2009, 83(2):e66-67.
[8]	Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia[J]. Pharmacotherapy, 2009, 29(1) :64-73.
[9]	Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats[J]. J Pharmacol Exp Ther, 2002, 302(3):1129-1134.
[10]	Staller J. The effect of long-term antipsychotic treatment on prolactin[J]. J Child Adolesc Psychopharmacol, 2006, 16(3):317-326.
[11]	Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-Hydroxy metabolite of risperidone in elevating blood prolactin levels[J]. Am J Psychiatr, 2005, 162(5):1010-1012.
[12]	Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite[J]. Hum Psychopharmacol, 2006, 21(8): 529-532.
[13]	Citrome L. Paliperidone: quo vadis?[J]. Int J Clin Pract, 2007, 61(4):653-662.
[14]	Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies[J]. J Clin Psychiatr, 2008, 69(5): 817-829.
[15]	Einarson TR,Hemels ME,Nuamah I,et al.An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate[J].Ann Pharmacother,2012,46(10):1322-1330.
[16]	Molitch ME. Drugs and prolactin[J]. Pituitary, 2008, 11(2): 209-218.
[17]	Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia[J]. Clin Obstet Gynecol, 2003, 46 (2):349-362.
[18]	郭金宏,曹长安. 溴隐亭治疗抗精神病药物致高泌乳素血症的临床研究[J]. 神经疾病与精神卫生, 2003, 3(3) : 244.
[19]	Lee MS, Song HC, An H, et al. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study[J]. Psychiatr Clin Neurosci, 2010, 64(1):19-27.
[20]	Rocha FL, Hara C, Ramos MG. Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia[J]. Prog Neuropsychopharmacol Biol Psychiatr, 2010, 34(6):1153-1154.
[21]	魏桂林, 徐小薇, 李大魁. 药物与高催乳素血症[J]. 药物不良反应杂志, 2000, 2(2):73-75.

Message Board

Clinical practice of an endocrinology clinical pharmacists participating in the treatment of a patient with diabetes and hyperprolactinemia

doi: 10.3969/j.issn.1006-0111.2015.02.020

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views